These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39341857)

  • 1. Dual activity of Minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment.
    Koksalar Alkan F; Caglayan AB; Alkan HK; Benson E; Gunduz YE; Sensoy O; Durdagi S; Zarbaliyev E; Dyson G; Assad H; Shull A; Chadli A; Shi H; Ozturk G; Korkaya H
    Sci Rep; 2024 Sep; 14(1):22487. PubMed ID: 39341857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual activity of Minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment.
    Korkaya H; Koksalar Alkan F; Caglayan A; Alkan H; Benson E; Gunduz Y; Sensoy O; Durdagi S; Zarbaliyev E; Dyson G; Assad H; Shull A; Chadli A; Shi H; Ozturk G
    Res Sq; 2024 Feb; ():. PubMed ID: 38464167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
    Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
    J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A self-targeting MOFs nanoplatform for treating metastatic triple-negative breast cancer through tumor microenvironment remodeling and chemotherapy potentiation.
    Wu H; Jin M; Liu Y; Wang S; Liu C; Quan X; Jin M; Gao Z; Jin Y
    Int J Pharm; 2024 Oct; 664():124625. PubMed ID: 39182743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
    Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
    J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minnelide suppresses GVHD and enhances survival while maintaining GVT responses.
    Copsel SN; Garrido VT; Barreras H; Bader CS; Pfeiffer B; Mateo-Victoriano B; Wolf D; Gallardo M; Paczesny S; Komanduri KV; Benjamin CL; Villarino AV; Saluja AK; Levy RB
    JCI Insight; 2024 Apr; 9(9):. PubMed ID: 38602775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
    Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
    Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
    Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
    FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.
    Banerjee S; Modi S; McGinn O; Zhao X; Dudeja V; Ramakrishnan S; Saluja AK
    Clin Cancer Res; 2016 Jan; 22(2):415-25. PubMed ID: 26405195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
    Arora N; Alsaied O; Dauer P; Majumder K; Modi S; Giri B; Dudeja V; Banerjee S; Von Hoff D; Saluja A
    PLoS One; 2017; 12(2):e0171827. PubMed ID: 28192510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
    Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide and Its Derivatives as Cancer Therapies.
    Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
    Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.
    Chen Y; Yang J; Wang C; Wang T; Zeng Y; Li X; Zuo Y; Chen H; Zhang C; Cao Y; Sun C; Wang M; Cao X; Ge X; Liu Y; Zhang G; Deng Y; Peng C; Lu A; Lu J
    J Exp Clin Cancer Res; 2024 Jul; 43(1):207. PubMed ID: 39054545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer.
    Xia J; Zhang L; Peng X; Tu J; Li S; He X; Li F; Qiang J; Dong H; Deng Q; Liu C; Xu J; Zhang R; Liu Q; Hu G; Liu C; Jiang YZ; Shao ZM; Chen C; Liu S
    Cancer Res; 2024 Jul; 84(14):2282-2296. PubMed ID: 38657120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer.
    He J; Peng T; Peng Y; Ai L; Deng Z; Wang XQ; Tan W
    J Am Chem Soc; 2020 Feb; 142(6):2699-2703. PubMed ID: 31910009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
    Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.